You are viewing: UK AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The UK AI in Life Science Market was valued at $990.5 Million in 2026 and projected to reach to $3135.3 Million by 2031, representing a compound annual growth rate of CAGR 25.9%. The UK AI in Life Science Market is poised for exceptional growth through 2031, driven by strong regulatory support, substantial R&D investments, and the NHS's digital transformation initiatives.

UK AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK AI in Life Science Market Trends and Insights

  • The UK's strong healthcare infrastructure, advanced research institutions, and significant investment in digital health technologies are driving rapid adoption of AI solutions across drug discovery, clinical diagnostics, and personalized medicine.
  • The UK's position as a global life sciences hub, combined with supportive regulatory frameworks and substantial government funding for AI innovation, positions the market for accelerated growth throughout the forecast period. During the 2026–2031 period, the UK market will benefit from increasing collaboration between pharmaceutical companies, biotech firms, and AI developers.
  • The UK's emphasis on precision medicine and genomic research is creating substantial demand for AI-powered analytics and predictive modeling tools.
  • Healthcare providers across the UK are increasingly integrating AI into clinical workflows to improve patient outcomes and operational efficiency, further propelling market expansion at a 25.9% compound annual growth rate..

Key Market Statistics

  • CAGR (2026-2031) CAGR 25.9%
  • Market Size, 2026 ~USD 990.5 Million
  • Forecast, 2031 ~USD 3135.3 Million
  • Country UK

UK AI in Life Science Market Overview

Market Valuation Growth :

The UK AI in Life Science Market is valued at $990.5 million in 2026 and is projected to expand to $3,135.3 million by 2031, representing a robust 25.9% CAGR over the forecast period.

Healthcare Infrastructure Advantage :

The UK's world-class NHS infrastructure, combined with leading research institutions like Oxford and Cambridge, creates an ideal ecosystem for AI adoption in drug discovery, diagnostics, and personalized medicine applications.

Digital Health Investment :

Significant government and private sector investment in digital health technologies is accelerating AI integration across UK life science organizations, positioning the country as a European innovation leader.

Clinical Application Expansion :

UK healthcare providers are rapidly deploying AI solutions for clinical diagnostics, genomic analysis, and treatment personalization, driving market growth across both public and private sectors.

UK AI in Life Science Market Dynamics

  • The convergence of advanced AI capabilities with the UK's established pharmaceutical and biotech sectors creates significant opportunities for innovation in drug development and precision medicine.
  • Collaboration between academic institutions and commercial enterprises is accelerating the commercialization of AI-driven solutions.
  • The market will benefit from increasing adoption of machine learning for clinical trial optimization and patient stratification, supported by favorable government policies and funding mechanisms that encourage AI integration in healthcare..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • The UK AI in Life Science Market will grow from $990.5M (2026) to $3,135.3M (2031) at a 25.9% CAGR.
    • The UK's advanced research ecosystem and regulatory support are accelerating AI adoption in drug discovery and diagnostics.
    • UK healthcare providers are rapidly integrating AI into clinical workflows to enhance patient outcomes and operational efficiency.
    • The UK's emphasis on precision medicine and genomic research is driving substantial demand for AI-powered analytics solutions.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    UK AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    UK: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES5567.885.3107.9134.9170.2213.4264.625.4
    BIOTECHNOLOGY COMPANIES130.2161.7204.8260.8328.4417.4527.2658.326.3
    CRO & CDMO107.8133167.5212265.4335.2420.8522.225.5
    DIAGNOSTIC COMPANIES52.164.581.5103.5130164.8207.5258.526
    OTHER END USERS34.642.653.567.584.2106.1132.8164.225.2
    PHARMACEUTICAL COMPANIES254314.8398506635.9806.71016.91267.426.1
    TOTAL633.6784.3990.51257.81578.72000.42518.63135.325.9

    Target Audience

    • UK Pharmaceutical Companies : Need market intelligence to assess AI investment opportunities in drug discovery and development, understand competitive positioning, and identify acquisition targets within the UK life science ecosystem.
    • NHS and Healthcare Providers : Require data-driven insights to evaluate AI solution vendors, justify digital transformation budgets, and understand adoption trends across UK clinical settings for diagnostics and personalized treatment.
    • AI and Biotech Startups : Seek UK market validation, funding landscape analysis, and growth opportunity identification to develop business cases, attract investors, and plan market entry strategies in British life sciences.
    • Healthcare Technology Investors : Need comprehensive UK market forecasts, segment analysis, and competitive intelligence to identify high-growth investment opportunities and assess portfolio companies' market potential.
    • Government and Policy Bodies : Require market data to inform digital health strategy, allocate R&D funding, and develop policies that support UK life science innovation and AI adoption across the healthcare sector.

    Key Companies in the UK AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Access precise valuation data for the UK market with detailed 2026-2031 forecasts, enabling accurate budget allocation and investment planning tailored to the British life science sector.
    • Competitive Landscape Intelligence : Understand UK-based AI vendors, NHS adoption patterns, and regional competitive dynamics to identify partnership opportunities and market entry strategies specific to the British healthcare ecosystem.
    • Regulatory & Policy Insights : Gain clarity on UK-specific regulatory frameworks, MHRA guidelines, and government digital health initiatives that directly impact AI implementation timelines and market opportunities.
    • Investment Decision Support : Make informed investment decisions with UK market segmentation data covering drug discovery, diagnostics, and personalized medicine applications with localized growth projections.
    • Strategic Growth Planning : Leverage UK-focused trend analysis and adoption forecasts to develop targeted go-to-market strategies for life science organizations, healthcare providers, and AI solution providers.

    Frequently asked questions

    What is the current size of the UK AI in Life Science Market?

    The UK AI in Life Science Market is valued at $990.5 million in 2026 and is expected to grow to $3,135.3 million by 2031.

    What is the growth rate of the UK AI in Life Science Market?

    The UK market is projected to grow at a compound annual growth rate (CAGR) of 25.9% from 2026 to 2031.

    What are the main drivers of AI adoption in the UK life sciences sector?

    Key drivers include the UK's strong healthcare infrastructure, advanced research institutions, government funding for AI innovation, and increasing demand for precision medicine and genomic research applications.

    How is the UK positioned compared to other European markets for AI in life sciences?

    The UK is a global life sciences hub with supportive regulatory frameworks, substantial investment in digital health, and strong collaboration between pharmaceutical, biotech, and AI companies, positioning it as a leading market in Europe.

    Which applications are driving the most growth in the UK AI in Life Science Market?

    Drug discovery, clinical diagnostics, personalized medicine, AI-powered analytics, and predictive modeling tools are the primary applications driving growth in the UK market.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status